

**Table 3. (continued)**

Exon	Domain	NM_No.	Nucleotide Change	Amino Acid Change	Age at Onset	Hearing Level	Origin of Family	Reference
18	Motor	NM_016239	c.5189T>C	p.G1730P	-	Severe to profound	Pakistan	21
19	Motor	NM_016239	c.5305A>G	p.T1769A	-	Severe to profound	Iran	23
21	Motor	NM_016239	c.5421delT	p.F1807LfsX6	-	Severe to profound	Iran	23
21	Motor	NM_016239	c.5492G>T	p.G1831V	-	Profound	Turkey	34
Intron 22	-	NM_016239	c.5650-1G>A	p.A1884fs	-	-	Turkey	35
23	Motor	NM_016239	c.5810G>A	p.R1937H	-	Severe to profound	Iran	23
23	Motor	NM_016239	c.5808_5814delCCGTGGC	p.R1937TfsX10	Congenital or prelingual	Severe to profound	Turkey	30
25	IQ Motif	NM_016239	c.5925G>A	p.W1975X	-	Severe to profound	Iran	23
26	IQ Motif	NM_016239	c.5978G>A	p.R1993Q	First decade	Severe	Japan	This study
27	-	NM_016239	c.6061C>T	p.Q2021X	-	Severe to profound	Pakistan	21
28	MyTH4	NM_016239	c.6217C>T	p.P2073S	Congenital	Profound	Iran	22
29	MyTH4	NM_016239	c.6331A>T	p.N2111Y	Congenital	Profound	India	36
29	MyTH4	NM_016239	c.6306_6307insG	p.A2104CfsX18	-	-	China	7
29	MyTH4	NM_016239	c.6337A>T	p.I2113F	Congenital	Profound	Indonesia	36
29	MyTH4	NM_016239	c.6340G>A	p.V2114M	-	-	China	7
29	MyTH4	NM_016239	c.6371G>A	p.R2124Q	Congenital	Profound	Iran	22
29	MyTH4	NM_016239	c.6487delG	p.A2153fs	Prelingual	Profound	Japan	This study
30	MyTH4	NM_016239	c.6614C>T	p.T2205I	Congenital	Moderate	North America	20
32	-	NM_016239	c.6703T>C	p.S2235P	Second decade	Moderate	Japan	This study
31	-	NM_016239	c.6731G>A	p.G2244E	Prelingual	Severe to profound	Pakistan, Japan	21, this study
31	-	NM_016239	c.6796G>A	p.V2266M	-	Severe to profound	Pakistan, Turkey	21
Intron 36	-	NM_016239	c.7395+3G>C	-	-	Severe to profound	Tunisia	33
39	SnAPC2 like	NM_016239	c.7801A>T	p.K2601X	Congenital	Profound	India	36
41	SnAPC2 like	NM_016239	c.7982C>A	p.S2661X	-	-	Turkey	35
46	-	NM_016239	c.8148G>T	p.Q2716H	Congenital	Profound	Pakistan	20
43	-	NM_016239	c.8158G>C	p.D2720H	-	Severe to profound	Pakistan	21
43	-	NM_016239	c.8183G>A	p.R2728H	-	-	Jewish, China	7, 29

Table 3. (continued)

Exon	Domain	NM_No.	Nucleotide Change	Amino Acid Change	Age at Onset	Hearing Level	Origin of Family	Reference
43	-	NM_016239	c.8198A>C	p.E2733A	Congenital	Profound	Japan	This study
43	-	NM_016239	c.8324G>A	p.R2775H	-	-	China	7
46	PH like	NM_016239	c.8467G>A	p.D2823N	-	Severe to profound	Iran	23
48	SH3	NM_016239	c.8767C>T	p.R2923X	-	-	China	6
Intron 49	-	NM_016239	c.8968-1G>C	-	-	Profound	Turkey	34
49	SH3	NM_016239	c.8821_8822insTG	p.V2940fsX3034	-	Severe to profound	Pakistan	21
Intron 53	-	NM_016239	c.9229+1G>A	-	-	Severe to profound	Tunisia	33
59	MyTH4	NM_016239	c.9413T>A	p.L3138Q	Congenital or prelingual	Profound	Japan	3, this study
59	MyTH4	NM_016239	c.9478C>T <sup>b</sup>	p.L3160F <sup>b</sup>	Congenital	Severe to profound	Pakistan	8, 21, This study
59	MyTH4	NM_016239	c.9517G>A	p.G3173R	First decade	Severe	Japan	This study
65	FERM central	NM_016239	c.9958_9961delGACT	p.D3320fs	First decade	Severe to profound	Brazil	37
65	FERM central		c.9995_10002dupGCCGGCCC	p.S3335AfsX121	Congenital or prelingual	Severe to profound	Turkey	30
67	FERM central	NM_016239	c.10249_10251delTCC	p.F3417del	Congenital	Profound	Japan	This study
67	FERM central	NM_016239	c.10263C>G	p.I3421M	10-19 y	Moderate to severe	Japan	This study
68	FERM central	NM_016239	c.10474C>T	p.Q3492X	-	Severe to profound	Pakistan	21
69	FERM central	NM_016239	c.10573delA	p.S3525fs	Prelingual	Severe to profound	Brazil	37

<sup>a</sup>-, not available.

<sup>b</sup>Controversial variant (see Discussion).

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases (H24-Nanchiou(Nan)-Ippan-032) and Comprehensive Research on Disability Health and Welfare (H25-Kankaku-Ippan-002) from the Ministry of Health, Labour and Welfare, Japan (S.U.) and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (S.U.).

### References

- Hereditary Hearing Loss Homepage. <http://hereditaryhearingloss.org/>. Updated May 19, 2014. Accessed December 12, 2014.
- Krendel M, Mooseker MS. Myosins: tails (and heads) of functional diversity. *Physiology*. 2005;20:239-251.
- Yano T, Ichinose A, Nishio S, Kobayashi Y, Sato H, Usami S. Novel mutation of *MYO15A* associated with hearing loss in a Japanese family. *J Clin Case Rep*. 2013;3:319.
- Diaz-Horta O, Duman D, Foster J II, et al. Whole-exome sequencing efficiently detects rare mutations in autosomal recessive nonsyndromic hearing loss. *PLoS One*. 2012;7(11):e50628.
- Fattahi Z, Shearer AE, Babanejad M, et al. Screening for *MYO15A* gene mutations in autosomal recessive nonsyndromic, GJB2 negative Iranian deaf population. *Am J Med Genet A*. 2012;158A(8):1857-1864.
- Woo HM, Park HJ, Baek JI, et al. Whole-exome sequencing identifies *MYO15A* mutations as a cause of autosomal recessive nonsyndromic hearing loss in Korean families. *BMC Med Genet*. 2013;14:72.
- Yang T, Wei X, Chai Y, Li L, Wu H. Genetic etiology study of the non-syndromic deafness in Chinese Hans by targeted next-generation sequencing. *Orphanet J Rare Dis*. 2013;14:8:85.
- Miyagawa M, Nishio SY, Ikeda T, Fukushima K, Usami S. Massively parallel DNA sequencing successfully identifies new causative mutations in deafness genes in patients with cochlear implantation and EAS. *PLoS One*. 2013;8:e75793.
- Chang X, Wang K. ANNOVAR; annotating genetic variants for personal genomes via the web. *J Med Genet*. 2012;49:433-436.
- Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variation from high-throughput sequencing data. *Nucleic Acid Res*. 2010;38:e164.
- Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012;491(7422):56-65.
- NHLBI Exome Sequencing Project (ESP) Exome Variant Server. <http://evs.gs.washington.edu/EVS/>. Accessed February 10, 2015.
- Narahara M, Higasa K, Nakamura S, et al. Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants. *PLoS One*. 2014;9(6):e100924.
- Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc*. 2009;4(7):1073-1081.
- Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010;7(4):248-249.
- Schwarz JM, Rodelsperger C, Schuelke M, et al. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods*. 2010;7(8):575-576.
- Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. *Nucleic Acids Res*. 2011;39(17):e118.
- Shihab HA, Gough J, Cooper DN, et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. *Hum Mutat*. 2013;34(1):57-65.
- Cooper GM, Stone EA, Asimenos G, et al. Distribution and intensity of constraint in mammalian genomic sequence. *Genome Res*. 2005;15(7):901-913.
- Liburd N, Ghosh M, Riazuddin S, et al. Novel mutations of *MYO15A* associated with profound deafness in consanguineous families and moderately severe hearing loss in a patient with Smith-Magenis syndrome. *Hum Genet*. 2001;109(5):535-541.
- Nal N, Ahmed ZM, Erkal E, et al. Mutational spectrum of *MYO15A*: the large N-terminal extension of myosin XVA is required for hearing. *Hum Mutat*. 2007;28(10):1014-1019.
- Shearer AE, Hildebrand MS, Webster JA, et al. Mutations in the first MyTH4 domain of *MYO15A* are a common cause of DFNB3 hearing loss. *Laryngoscope*. 2009;119(4):727-733.
- Fattahi Z, Shearer AE, Babanejad M, et al. Screening for *MYO15A* gene mutations in autosomal recessive nonsyndromic, GJB2 negative Iranian deaf population. *Am J Med Genet A*. 2012;158A(8):1857-1864.
- Usami S, Nishio SY, Nagano M, Abe S, Yamaguchi T, Deafness Gene Study Consortium. Simultaneous screening of multiple mutations by invader assay improves molecular diagnosis of hereditary hearing loss: a multicenter study. *PLoS One*. 2012;7(2):e31276.
- Wagatsuma M, Kitoh R, Suzuki H, Fukuoka H, Takumi Y, Usami S. Distribution and frequencies of *CDH23* mutations in Japanese patients with non-syndromic hearing loss. *Clin Genet*. 2007;72(4):339-344.
- Shearer AE, Eppsteiner RW, Booth KT, et al. Utilizing ethnic-specific differences in minor allele frequency to recategorize reported pathogenic deafness variants. *Am J Hum Genet*. 2014;95(4):445-453.
- Wilson BS. The future of cochlear implants. *Br J Audiol*. 1997;31(4):205-225.
- Probst FJ, Fridell RA, Raphael Y, et al. Correction of deafness in shaker-2 mice by an unconventional myosin in a BAC transgene. *Science*. 1998;29;280(5368):1444-1447.
- Brownstein Z, Friedman LM, Shahin H, et al. Targeted genomic capture and massively parallel sequencing to identify genes for hereditary hearing loss in Middle Eastern families. *Genome Biol*. 2011;12(9):R89.

30. Cengiz FB, Duman D, Sirmaci A, et al. Recurrent and private *MYO15A* mutations are associated with deafness in the Turkish population. *Genet Test Mol Biomarkers*. 2010;14(4):543-550.
31. Intiaz F, Taibah K, Ramzan K, et al. A comprehensive introduction to the genetic basis of non-syndromic hearing loss in the Saudi Arabian population. *BMC Med Genet*. 2011;12:91.
32. Bashir R, Fatima A, Naz S. Prioritized sequencing of the second exon of *MYO15A* reveals a new mutation segregating in a Pakistani family with moderate to severe hearing loss. *Eur J Med Genet*. 2012;55(2):99-102.
33. Belguith H, Aifa-Hmani M, Dhouib H, et al. Screening of the DFNB3 locus: identification of three novel mutations of *MYO15A* associated with hearing loss and further suggestion for two distinctive genes on this locus. *Genet Test Mol Biomarkers*. 2009;13(1):147-151.
34. Kalay E, Uzumcu A, Krieger E, et al. *MYO15A* (DFNB3) mutations in Turkish hearing loss families and functional modeling of a novel motor domain mutation. *Am J Med Genet A*. 2007;143A(20):2382-2389.
35. Duman D, Sirmaci A, Cengiz FB, Ozdag H, Tekin M. Screening of 38 genes identifies mutations in 62% of families with nonsyndromic deafness in Turkey. *Genet Test Mol Biomarkers*. 2011;15(1-2):29-33.
36. Wang A, Liang Y, Fridell RA, et al. Association of unconventional myosin *MYO15* mutations with human non-syndromic deafness DFNB3. *Science*. 1998;280(5368):1447-1451.
37. Lezirovitz K, Pardon E, de Mello Auricchio MT, et al. Unexpected genetic heterogeneity in a large consanguineous Brazilian pedigree presenting deafness. *Eur J Hum Genet*. 2008;16(1):89-96.



# Vestibular Functions of Hereditary Hearing Loss Patients with *GJB2* Mutations

Keita Tsukada Hisakuni Fukuoka Shin-ichi Usami

Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto City, Japan

## Key Words

*GJB2* gene · Caloric test · Cervical vestibular evoked myogenic potential

## Abstract

**Objectives:** Mutations in the *GJB2* gene have been of particular interest as it is the most common causative gene for congenital deafness in all populations. Detailed audiological features, including genotype-phenotype correlations, have been well documented. However, in spite of abundant gene as well as protein expression in the vestibular end organs, neither vestibular symptoms nor vestibular functions have yet been elucidated. In the present study, vestibular functions were evaluated in patients diagnosed with *GJB2*-related deafness. **Subjects and Methods:** Vestibular functions were evaluated by caloric test and cervical vestibular evoked myogenic potential (cVEMP) testing in 24 patients with biallelic *GJB2* mutations. **Results and Discussion:** Twenty-one of 23 patients (91.3%) had normal caloric responses and significantly lower cVEMP amplitudes than the control subjects. In the patients who were able to undergo vestibular testing, the mostly normal reactions to caloric testing indicated that the lateral semicircular canal was intact. However, the majority of *GJB2* patients showed low cVEMP reactions, indicating a saccular defect.

© 2015 S. Karger AG, Basel

## Introduction

Hereditary hearing loss affects about 1 in 1,000 infants in developed countries, and genetic causes account for at least 50% of all childhood hearing loss [Morton, 1991]. Nowadays, it is known that mutations in various kinds of genes cause hearing loss.

Mutations in the *GJB2* gene are the most common genetic cause of both congenital and hereditary hearing loss worldwide. A series of previous studies have demonstrated that about 15–25% of patients with congenital hearing loss have *GJB2* mutations [Azaiez et al., 2004; Dai et al., 2009; Tsukada et al., 2010; Chan and Chang, 2014]. To date, more than 100 *GJB2* variations have been reported (see the connexin-deafness homepage: <http://www.davinc.crg.es/deafness>), and hearing loss ranges from mild to profound according to differences in the genotype; therefore, genotype-phenotype correlations are well documented, and this type of hearing loss is thought to be nonprogressive. Detailed audiological features, including genotype-phenotype correlations and progression, in patients with these mutations have been well studied [Snoeckx et al., 2005; Tsukada et al., 2010; Minami et al., 2013; Chan and Chang, 2014].

However, there have been only a few reports on vestibular function despite abundant *GJB2* gene and protein expression in the vestibular end organs [Kikuchi et

al., 1994; Forge et al., 2003]. Here we summarize the results of our comprehensive study on vestibular function in patients with hearing loss caused by *GJB2* mutations.

## Subjects and Methods

Twenty-four patients (7 males and 17 females) with biallelic *GJB2* mutations underwent cervical vestibular evoked myogenic potential (cVEMP) and/or caloric testing in this study. Caloric testing was performed for 23 subjects (mean age 16.3 years, range 5–60), and cVEMP was assessed for 22 subjects. As the cVEMP results were affected by cochlear implantation, we excluded cochlear-implanted ears from the final analysis, resulting in the cVEMP results for 36 ears of 21 subjects (mean age 15.0 years, range 5–41) being included.

As a control, vestibular testing was performed for 70 unaffected ears with normal hearing in patients with unilateral hearing loss caused by mumps, unilateral cochlear nerve deficiency or sudden deafness. Caloric testing was performed in 64 of these 70 subjects, with the data for 43 of the subjects (mean age 16.8 years, range 5–62) used as age-matched controls. cVEMP testing was also performed in 69 of the 70 subjects, with the data for 42 of the subjects (mean age 14.6 years, range 5–42) used as age-matched controls. Informed written consent was obtained from all subjects, control subjects and, in the case of minors, the next of kin, caretakers or guardians prior to participation in the study. The study and consent procedure were approved by the Ethical Committee of Shinshu University.

### Mutation Analysis

To identify *GJB2* mutations, a DNA fragment containing the entire coding region was amplified using the primer pair Cx48U/Cx1040L, as described elsewhere [Abe et al., 2000]. Polymerase chain reaction (PCR) products were sequenced and analyzed with an ABI sequencer 3130XL (Applied Biosystems, Life Technologies, Carlsbad, Calif., USA).

### Audiological Evaluation

The hearing level was determined by pure-tone audiometry. The average threshold in the conversation frequencies (0.5, 1.0, 2.0 and 4.0 kHz) was calculated for the better ear, and the severity of hearing loss was categorized as mild (20–40 dB), moderate (41–70 dB), severe (71–95 dB) or profound (>95 dB) (see GENDEAF recommendations: <http://hereditaryhearingloss.org>).

### Vestibular Tests

The patients were examined by caloric testing and cVEMP testing to obtain data on semicircular canal function and otolith function, respectively.

In the cVEMP testing, electromyography (EMG) was performed using a pair of surface electrodes mounted on the upper half and sternal head of the sternocleidomastoid muscle, respectively. The electrographic signal was recorded using a Neuropack evoked potential recorder (Nihon Kohden Co. Ltd., Tokyo, Japan). Clicks lasting for 0.1 ms at 105 dB nHL were presented through a headphone. The stimulation rate was 5 Hz, the bandpass filter intensity was 20–2,000 Hz, and analysis time was 50 ms. The responses to 200 stimuli were averaged twice. As the P13–N23 amplitude of the cVEMP based on the unrectified EMG activity is

correlated with sternocleidomastoid muscle activity during the test [Colebatch et al., 1994], we measured sternocleidomastoid muscle activity using the background-integrated EMG response; i.e., the area under the averaged rectified EMG curve from –20 to 0 ms before sound stimulation. The correction of the P13–N23 amplitude was calculated as follows [Shojaku et al., 2001]:

corrected amplitude = P13–N23 amplitude of the averaged unrectified EMG ( $\mu\text{V}$ )/the average background-integrated EMG of 20 ms ( $\mu\text{V}$ ).

In the caloric testing, the maximum slow phase velocity (SPV) was measured by cold water irrigation (20°C, 5 ml, 20 s). We defined an SPV value below 10°/s as representing areflexia and a value between 10 and 20°/s as hypoflexia.

### Statistical Analysis

For all analyses, SPSS for Windows software (IBM Co., Chicago, Ill., USA) was used, and Mann-Whitney U tests were applied when comparing differences between patients with *GJB2* mutations and the normal controls. Correlations between the severity of hearing and vestibular functions were calculated using Pearson's correlation coefficient.

## Results

The *GJB2* mutations and vestibular and audiological results for all patients are summarized in table 1.


### Semicircular Canal Function

Only 2 out of the 23 patients (8.7%) who underwent caloric testing showed an areflexic (G10) or hypoflexic (G3) response in the unilateral ear.


Figure 1 shows a comparison between caloric test results for the patients with *GJB2* mutations and normal controls. There was no statistically significant difference in the median SPV value between patients with *GJB2* mutations and the control subjects (31.9 vs. 40.8°/s;  $p = 0.121$ , Mann-Whitney U test).

### Saccular Function

We performed cVEMP testing on 36 ears of 21 patients with *GJB2* mutations (mean age 15.0 years, range 5–41) included in this study. Figure 2 shows a comparison between the corrected amplitude of cVEMP for the patients with *GJB2* mutations and age-matched normal controls. The median corrected amplitude was 0.570 in the patients with *GJB2* mutations, which was statistically lower ( $p < 0.001$ , Mann-Whitney U test) than that of the normal controls ( $n = 42$ ; 1.41). Seventeen out of 21 patients with *GJB2* mutations (80.1%), or 22 out of 36 ears (61.1%), showed a value lower than 0.64, which was the cutoff for amplitude in the cVEMP results for the lowest 5% of the normal control subjects.



**Fig. 1.** The mean SPV in the patients with biallelic *GJB2* mutations and the control group. n.s. = No statistically significant difference (Mann-Whitney U test).




**Fig. 2.** The mean cVEMP corrected amplitude of the patients with biallelic *GJB2* mutations and the control group. \*  $p < 0.001$ , Mann-Whitney U test.

**Table 1.** Results of audiological and vestibular testing of patients with biallelic *GJB2* mutations


Patient No.	Mutation	Age, years	Sex	Vertigo	Hearing levels	Caloric test, degrees/s		cVEMP	
						R	L	R	L
G1	c.176–191 16bp del/c.235delC	8	M	–	profound	47.9	61.92 <sup>1</sup>	0.42	0 <sup>1</sup>
G2	c.235delC/p.M93I	10	F	–	moderate	38.23	46.38	0.46	1.54
G3	c.176–191 16bp del/c.235delC	12	F	–	profound	9.34	24.23	0.42	0.48
G4	c.235delC/c.235delC	7	M	–	profound	22.89	41.24 <sup>1</sup>	0	1.860 <sup>1</sup>
G5	c.235delC/p.R143W	20	M	–	profound	22.18	25.82	0.4	0.86
G6	c.235delC/p.G45E Y136X	25	F	–	severe	20.83	70.87	1.28	0.52
G7	c.235delC/p.G45E Y136X	22	F	–	profound	34.64 <sup>1</sup>	24.87	0.200 <sup>1</sup>	1
G8	p.V37I/p.V37I	9	M	–	moderate	43.69	48.54	1	0.5
G9	c.235delC/c.235delC	6	M	–	profound	59.27 <sup>1</sup>	88.8	0.860 <sup>1</sup>	1.4
G10	p.G45E Y136X/c.299–300delAT	6	F	–	severe	0	33.18	1.22	1.92
G11	c.176–191del 16bp/p.R143W	17	F	–	profound	90.71	25.48	0.6	0.38
G12	c.235delC/c.235delC	6	M	–	profound	34.33	39.21	1.26	0
G13	c.235delC/c.235delC	29	F	–	moderate	n.a.	n.a.	0.6	0.96
G14	p.G45E Y136X/c.176–191del 16bp	60	F	–	profound	45.92	50.15 <sup>1</sup>	n.a.	n.a. <sup>1</sup>
G15	c.235delC/c.235delC	16	F	–	profound	30.6	23.17	n.a.	n.a.
G16	c.235delC/p.R143W	10	F	–	profound	27.27	39.33 <sup>1</sup>	0.86	0 <sup>1</sup>
G17	c.235delC/p.R143W	12	F	–	profound	20.21 <sup>1</sup>	20.54 <sup>1</sup>	0 <sup>1</sup>	0 <sup>1</sup>
G18	c.235delC/p.G45E Y136X	13	F	–	moderate	68.89	81.2	0.4	0
G19	c.235delC/c.235delC	25	F	–	moderate	21.22	25.91	0.54	0.72
G20	c.235delC/c.235delC	28	F	–	profound	22.93	28.95	0.48	0.46
G21	c.235delC/p.T86R	5	M	–	profound	57.72 <sup>1</sup>	64.81	0 <sup>1</sup>	0
G22	c.235delC/p.G45E Y136X	9	F	–	severe	31.93	35.85	0.46	1.04
G23	c.235delC/p.G45E Y136X	7	F	–	severe	27.43	24.26	1.02	0.64
G24	c.235delC/c.299–300delAT	41	F	–	profound	27.17	24.33	0.26	0.64

– = No symptom; n.a. = Not available.

<sup>1</sup> After cochlear implantation.



**Fig. 3.** The relationship between hearing level and caloric test results in patients with biallelic *GJB2* mutations.



**Fig. 4.** The relationship between hearing level and cVEMP results in patients with biallelic *GJB2* mutations.

#### *Relationship between Hearing Level and Vestibular Function*

With regard to the correlation between hearing level and vestibular functions, no statistically significant correlations were found between the severity of hearing level and SPV ( $R = -0.2$ ; fig. 3) or corrected amplitude of cVEMP results ( $R = -0.1$ ; fig. 4).

#### Discussion

*GJB2* encodes the connexin 26 (Cx26) protein, a member of the connexin family and related gap junction proteins. Connexins oligomerize to form hexameric hemichannels called connexons, which are present in the plasma membrane, where they can bind with connexons from adjacent cells to form functional gap junctions [Bruzzone et al., 1996]. The expression of *GJB2* has been documented in a variety of cells and tissues. In the cochlea, Cx26-containing gap junctions are proposed to maintain cochlear homeostasis and the circulation of metabolites, such as inositol 1,4, 5-trisphosphate, which is critical for cellular function and the survival of cochlea-supporting cells [Kikuchi et al., 1995; Martinez et al., 2009; Xu and Nicholson, 2013].

Previous immunocytochemical reports have shown the abundant expression of Cx26 in the supporting cells and fibrocytes of the rat and human vestibular end organs [Kikuchi et al., 1994; Forge et al., 2003], indicat-

ing that Cx26 functions in the vestibular end organs as well as in the cochlea. In spite of the abundant *GJB2* gene and protein expression in the vestibular end organs, there have been only a few reports on the vestibular function of patients with hearing loss caused by *GJB2* mutations, and the reports to date included only a small number of subjects or subjects with only heterozygous *GJB2* mutations [Todt et al., 2005; Kasai et al., 2010]. In this study, 21 out of 23 patients (91.3%) had normal caloric responses. On the other hand, the corrected amplitude of cVEMP for *GJB2* mutation patients was significantly lower than that for the normal control subjects, and 17 out of 21 patients (80.1%) showed a value that was lower than the lowest 5% of the normal control subjects. In the patients who were able to undergo vestibular testing, the mostly normal reactions to caloric testing indicated that the lateral semicircular canal was intact. However, the majority of *GJB2* mutation patients showed lower cVEMP reactions, revealing a saccular defect. In support of our results, previous reports also showed pathological cVEMP results in 3 of 5 (60%) patients [Kasai et al., 2010] and 5 of 7 (71.4%) patients [Todt et al., 2005] with *GJB2* mutations, and cochleo-saccular degeneration in human temporal bones with compound heterozygous *c.35delG* mutations [Jun et al., 2000].

There are a number of hypotheses regarding intact semicircular function and decreased saccular function. A previous report showed that the survival of vestibular hair



cells was observed in the utricle and crista ampullaris of Cx30<sup>-/-</sup> mice, although Cx30 is required for the survival of saccular hair cells [Qu et al., 2007]. Colocalization of Cx26 and Cx30 [Forge et al., 2003] in the vestibular organ suggested that they are coassembled from Cx26 and Cx30, so Cx26 may not be required for the survival of the utricle and ampullae in the same way. In addition to Cx26 and Cx30, RT-PCR and cDNA microarray analyses have shown that many other connexin genes, namely Cx29, Cx30 and Cx43, are expressed in the inner ear [Ahmad et al., 2003]. The vestibular organs express other connexins as well as Cx26 and Cx30, and it may be that channels containing these connexins can compensate for functional deficiencies caused by *GJB2* mutations in the semicircular canal.

Mutations in several different genes whose products appear to be involved in the maintenance of cochlear homeostasis cause nonsyndromic deafness and the death of outer hair cells [Steel and Kros, 2001], and both the targeted ablation of the mouse *cx26* gene from the organ of Corti and vestibular supporting cells [Cohen-Salmon et al., 2002] and the expression of a dominant negative *cx26* mutation [Kudo et al., 2003] also lead to the death of outer hair cells with no obvious effect on the vestibular organ. Therefore, the impairment of intercellular communication may have more generalized detrimental effects on cochlear homeostasis to which the organ of Corti is particularly sensitive, whereas the vestibular organs may be less dependent on efficient cell-to-cell communication. Both mice with a *cx30* deletion and mature mice with targeted ablation of *cx26* demonstrate hearing loss and do not generate endocochlear potentials [Cohen-Salmon et al., 2002; Teubner et al., 2003]; therefore, the disruption of intercellular communication and cochlear cell death may impair the ability to generate or maintain endocochlear potentials. The endocochlear potential is essential for auditory function in mammals, but there is no equivalent in the vestibular system [Wangemann, 1995]. It is well established that the utricle, ampullae and common crus of the semicircular canals all contain vestibular dark cell epithelia that secrete K<sup>+</sup> and distribute Cx26 [Masuda et al., 2001], while the saccule is devoid of vestibular dark cells [Kimura, 1969; Burnham and Stirling, 1984; Marcus and Shen, 1994; Marcus and Shipley, 1994]. Based on these and other observations [Sellick and Johnstone, 1972], it was proposed that the saccular endolymph originates from the cochlea by longitudinal flow or diffusion and is not produced in this organ. Changes in the endolymph in the cochlea might have a direct influence on the saccular

endolymph and induce degeneration and hypofunction of the saccule.

It is well known that a number of genotype-phenotype correlations are associated with hearing impairment [Snoeckx et al., 2005; Tsukada et al., 2010; Chan and Chang, 2014]. In this study, we evaluated the correlation between hearing level and vestibular function. There were no significant correlations between hearing level and SPV ( $R = -0.2$ ) or corrected amplitude of cVEMP results ( $R = -0.1$ ). As most of the patients in this study had a *c.235delC* mutation that is thought to be associated with a severer phenotype, we could not find any genotype-phenotype correlations among the vestibular functions. More genotypes should be evaluated in future to clarify the existence of any correlations.

In this study, no patients complained of vertigo or dizziness. Our previous study also showed only 4% (3/75) of patients with *GJB2* mutations had episodes of vertigo, dizziness or faintness [Tsukada et al., 2010]. Although associated symptoms of chronic saccular dysfunction are unknown, hearing loss in these patients is known to be congenital. Therefore, it is conceivable that vestibular compensation may occur in the central nervous system in spite of the presence of a saccular defect.

A previous report also described the results of utricular function using subjective haptic vertica [Todt et al., 2005]. Unfortunately, we could not investigate utricular function in this study, but we plan to undertake further work on utricular functions, such as ocular VEMP, in the near future.

## Conclusion

The high incidence of saccular defects in patients with *GJB2* mutations is indicative of the genetic background. Although hearing loss occurs in these patients, saccular dysfunctions are well compensated and may not decisively influence the quality of life.

This result will also facilitate the clinical application of genetic counseling for these patients and their families.

## Acknowledgments

We thank A.C. Apple-Mathews for her help in preparing the manuscript. This study was supported by a Health and Labour Sciences Research Grant for Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (to S.U.) and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (to S.U.).

## References

- Abe S, Usami S, Shinkawa H, Kelley PM, Kimberling WJ: Prevalent connexin 26 gene (*GJB2*) mutations in Japanese. *J Med Genet* 2000;37:41–43.
- Ahmad S, Chen S, Sun J, Lin X: Connexins 26 and 30 are co-assembled to form gap junctions in the cochlea of mice. *Biochem Biophys Res Commun* 2003;307:362–368.
- Azaiez H, Chamberlin GP, Fischer SM, Welp CL, Prasad SD, Taggart RT, del Castillo I, Van Camp G, Smith RJ: *GJB2*: the spectrum of deafness-causing allele variants and their phenotype. *Hum Mutat* 2004;24:305–311.
- Burnham JA, Stirling CE: Quantitative localization of Na-K pump sites in the frog sacculus. *J Neurocytol* 1984;13:617–638.
- Bruzzone R, White TW, Paul DL: Connections with connexins: the molecular basis of direct intercellular signaling. *Eur J Biochem* 1996;238:1–27.
- Chan DK, Chang KW: *GJB2*-associated hearing loss: systematic review of worldwide prevalence, genotype, and auditory phenotype. *Laryngoscope* 2014;124:E34–E53.
- Cohen-Salmon M, Ott T, Michel V, Hardelin JP, Perfettini I, Eybalin M, Wu T, Marcus DC, Wangemann P, Willecke K, Petit C: Targeted ablation of connexin 26 in the inner ear epithelial gap junction network causes hearing impairment and cell death. *Curr Biol* 2002;12:1106–1111.
- Colebatch JG, Halmagyi GM, Skuse NF: Myogenic potentials generated by a click-evoked vestibulocollic reflex. *J Neurol Neurosurg Psychiatry* 1994;57:190–197.
- Dai P, Yu F, Han B, Liu X, Wang G, Li Q, Yuan Y, Liu X, Huang D, Kang D, Zhang X, Yuan H, Yao K, Hao J, He J, He Y, Wang Y, Ye Q, Yu Y, Lin H, Liu L, Deng W, Zhu X, You Y, Cui J, Hou N, Xu X, Zhang J, Tang L, Song R, Lin Y, Sun S, Zhang R, Wu H, Ma Y, Zhu S, Wu BL, Han D, Wong LJ: *GJB2* mutation spectrum in 2,063 Chinese patients with nonsyndromic hearing impairment. *J Transl Med* 2009;14:7–26.
- Forge A, Becker D, Casalotti S, Edwards J, Marziano N, Nevill G: Gap junctions in the inner ear: comparison of distribution patterns in different vertebrates and assessment of connexin composition in mammals. *J Comp Neurol* 2003;467:207–231.
- Jun AI, McGuirt WT, Hinojosa R, Green GE, Fischel-Ghodsian N, Smith RJ: Temporal bone histopathology in connexin 26-related hearing loss. *Laryngoscope* 2000;110:269–275.
- Kasai M, Hayashi C, Iizuka T, Inoshita A, Kamiya K, Okada H, Nakajima Y, Kaga K, Ikeda K: Vestibular function of patients with profound deafness related to *GJB2* mutation. *Acta Otolaryngol* 2010;130:990–995.
- Kikuchi T, Adams JC, Paul DL, Kimura RS: Gap junction systems in the rat vestibular labyrinth: immunohistochemical and ultrastructural analysis. *Acta Otolaryngol* 1994;114:520–528.
- Kikuchi T, Kimura RS, Paul DL, Adams JC: Gap junctions in the rat cochlea: immunohistochemical and ultrastructural analysis. *Anat Embryol (Berl)* 1995;191:101–118.
- Kimura RS: Distribution, structure, and function of dark cells in the vestibular labyrinth. *Ann Otol Rhinol Laryngol* 1969;78:542–561.
- Kudo T, Kure S, Ikeda K, Xia AP, Katori Y, Suzuki M, Kojima K, Ichinohe A, Suzuki Y, Aoki Y, Kobayashi T, Matsubara Y: Transgenic expression of a dominant-negative connexin 26 causes degeneration of the organ of Corti and non-syndromic deafness. *Hum Mol Genet* 2003;12:995–1004.
- Marcus DC, Shen Z: Slowly activating, voltage-dependent K conductance is apical pathway for K secretion in vestibular dark cells. *Am J Physiol* 1994;267:857–864.
- Marcus DC, Shipley AM: Potassium secretion by vestibular dark cell epithelium demonstrated by vibrating probe. *Biophys J* 1994;66:1939–1942.
- Martínez AD, Acuña R, Figueroa V, Maripillan J, Nicholson B: Gap-junction channels dysfunction in deafness and hearing loss. *Antioxid Redox Signal* 2009;11:309–322.
- Masuda M, Usami S, Yamazaki K, Takumi Y, Shinkawa H, Kurashima K, Kunihiro T, Kan-zaki J: Connexin 26 distribution in gap junctions between melanocytes in the human vestibular dark cell area. *Anat Rec* 2001;262:137–146.
- Minami SB, Mutai H, Nakano A, Arimoto Y, Taiji H, Morimoto N, Sakata H, Adachi N, Masuda S, Sakamoto H, Yoshida H, Tanaka F, Morita N, Sugiuchi T, Kaga K, Matsunaga T: *GJB2*-associated hearing loss undetected by hearing screening of newborns. *Gene* 2013;532:41–45.
- Morton NE: Genetic epidemiology of hearing impairment. *Ann NY Acad Sci* 1991;630:16–31.
- Qu Y, Tang W, Dahlke I, Ding D, Salvi R, Söhl G, Willecke K, Chen P, Lin X: Analysis of connexin subunits required for the survival of vestibular hair cells. *J Comp Neurol* 2007;504:499–507.
- Sellick PM, Johnstone BM: The electrophysiology of the saccule. *Pflügers Arch* 1972;336:28–34.
- Shojaku H, Takemori S, Kobayashi K, Watanabe Y: Clinical usefulness of glycerol vestibular-evoked myogenic potentials: preliminary report. *Acta Otolaryngol Suppl* 2001;545:65–68.
- Snoeckx RL, Huygen PL, Feldmann D, Marlin S, Denoyelle F, Waligora J, Mueller-Malesinska M, Pollak A, Ploski R, Murgia A, Orzan E, Castorina P, Ambrosetti U, Nowakowska-Szyr-winska E, Bal J, Wiszniewski W, Janecke AR, Nekahm-Heis D, Seeman P, Bendova O, Kenna MA, Frangulov A, Rehm HL, Tekin M, Incesulu A, Dahl HH, du Sart D, Jenkins L, Lucas D, Bitner-Grindzic M, et al: *GJB2* mutations and degree of hearing loss: a multicenter study. *Am J Hum Genet* 2005;77:945–957.
- Steel KP, Kros CJ: A genetic approach to understanding auditory function. *Nat Genet* 2001;27:143–149.
- Teubner B, Michel V, Pesch J, Lautermann J, Cohen-Salmon M, Söhl G, Jahnke K, Winterhager E, Herberhold C, Hardelin JP, Petit C, Willecke K: Connexin 30 (*Gjb6*) deficiency causes severe hearing impairment and lack of endocochlear potential. *Hum Mol Genet* 2003;12:13–21.
- Todt I, Hennies HC, Basta D, Ernst A: Vestibular dysfunction of patients with mutations of connexin 26. *Neuroreport* 2005;16:1179–1181.
- Tsukada K, Nishio S, Usami S: Deafness Gene Study Consortium: A large cohort study of *GJB2* mutations in Japanese hearing loss patients. *Clin Genet* 2010;78:464–470.
- Wangemann P: Comparison of ion transport mechanisms between vestibular dark cells and strial marginal cells. *Hear Res* 1995;90:149–157.
- Xu J, Nicholson BJ: The role of connexins in ear and skin physiology – functional insights from disease-associated mutations. *Biochim Biophys Acta* 2013;1828:167–178.